Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
James Spicer(King's College London), Sophia N. Karagiannis(King's College London), Vineet Kwatra(Guy's and St Thomas' NHS Foundation Trust), Chris Selkirk(Cancer Research UK), Bristi Basu(University of Cambridge), Udai Banerji(Institute of Cancer Research), Silvana Canevari(Institute of Biomedical Technologies), Gary J. Doherty(Cambridge University Hospitals NHS Foundation Trust), Heather J. Bax(King's College London), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Atousa Khiabany(King's College London), Jitesh Chauhan(King's College London), Christopher J. Corrigan(King's College London), Cheryl Gillett(King's College London), Rowan Miller(Queen Mary University of London), Mano Nakamura(King's College London), Kristina M. Ilieva(King's College London), Ionut-Gabriel Funingana(University of Cambridge), Claire Barton(University of Hertfordshire), Stephen J. Till(Guy's Hospital), Hannah J. Gould(King's College London), Mariangela Figini(Fondazione IRCCS Istituto Nazionale dei Tumori), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Gareth J. Veal(Newcastle University), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Paul S. Jones(Cancer Research UK), George Nintos(Guy's and St Thomas' NHS Foundation Trust), Simon Carroll(Cancer Research UK), Sarah Mellor(Cancer Research UK), Giulia Pellizzari(King's College London), Sarah E. Pinder(St Thomas' Hospital), Chara Stavraka(King's College London)
Cited by 35
Related Papers
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
Targeting folate receptor alpha for cancer treatment
|Oncotarget|2016|447
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
|Nature Communications|2016|386